Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas

NCT00027625 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT00027625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00027625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 1
Overall status
Completed
Start date
January 28, 2002
Completion date
November 1, 2005
Enrollment
Not reported
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors